Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Dose-dense treatment for triple-negative breast cancer

Nature Reviews Clinical Oncology volume 7, pages 79–80 (2010)Cite this article

Subjects

Dose-dense chemotherapy has been proposed to improve breast cancer outcome due to its ability to prevent cancer cell repopulation; however, little is known about which patients benefit most from such scheduling. A pooled analysis of studies assessing dose-dense adjuvant chemotherapy has shown that most of the therapeutic benefit derived from dose-dense scheduling arises in patients with node-positive, triple-negative disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405–410 (1976).

    Article  CAS  Google Scholar 

  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).

  3. De Laurentiis, M. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26, 44–53 (2008).

    Article  CAS  Google Scholar 

  4. Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439 (2003).

    Article  CAS  Google Scholar 

  5. Sparano Joseph, A. et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N. Engl. J. Med. 358, 1663–1671 (2008).

    Article  Google Scholar 

  6. Venturini, M. et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J. Natl Cancer Inst. 97, 1724–1733 (2005).

    Article  CAS  Google Scholar 

  7. Berry, D. A. et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 295, 1658–1667 (2006).

    Article  CAS  Google Scholar 

  8. Norton, L. & Simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 61, 1307–1317 (1977).

    CAS  PubMed  Google Scholar 

  9. Del Mastro, L. et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br. J. Cancer 93, 7–14 (2005).

    Article  CAS  Google Scholar 

  10. Dang, C. et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J. Clin. Oncol. 26, 1216–1222 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, Canada

    Eitan Amir, Alberto Ocana, Orit Freedman & Bostjan Seruga

  2. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 401 Smyth Road, Ottawa, K1H, ON, Canada

    Mark Clemons

Authors
  1. Eitan Amir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Ocana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orit Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bostjan Seruga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eitan Amir.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amir, E., Ocana, A., Freedman, O. et al. Dose-dense treatment for triple-negative breast cancer. Nat Rev Clin Oncol 7, 79–80 (2010). https://doi.org/10.1038/nrclinonc.2009.231

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.231

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer